GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: WCK-5107 | WCK5107 | Zaynich® (cefepime and zidebactam)
zidebactam is an approved drug
Compound class:
Synthetic organic
Comment: Zidebactam (WCK 5107) is a novel β-lactamase inhibitor [1-2]. It was developed for the treatment of serious infections caused by highly drug-resistant Gram-negative pathogens.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Zidebactam (ZID) was investigated in combination with cefepime (FEP). The combination preparation is named WCK 5222, or FEP-ZID. The US FDA approved this combination therapy (as Zaynich®) in May 2026, to treat complicated urinary tract infections. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02707107 | MED Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy Volunteers | Phase 1 Interventional | Wockhardt | ||